Foamix Pharmaceuticals Ltd. Stock Nasdaq
Stocks
IL0011334385
Biotechnology & Medical Research
| Market Cap | 21.61M 18.63M 17.14M 16.08M 30.21M 2.04B 30.51M 203M 79.16M 1B 81.1M 79.38M 3.46B | P/E Ratio 2026 * |
-1.1x | P/E Ratio 2027 * | -1.01x |
|---|---|---|---|---|---|
| Enterprise Value | 21.61M 18.63M 17.14M 16.08M 30.21M 2.04B 30.51M 203M 79.16M 1B 81.1M 79.38M 3.46B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
95.44% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Foamix Pharmaceuticals Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 60 | 2020-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 40 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 53 | 2020-02-29 |
| Director | Title | Age | Since |
|---|---|---|---|
David Domzalski
BRD | Director/Board Member | 60 | 2020-02-29 |
Sharon Barbari
BRD | Director/Board Member | 72 | 2020-02-29 |
Steven Basta
BRD | Director/Board Member | 61 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -16.94% | - | - | 21.61M | |
| -2.86% | -0.26% | +57.57% | +110.98% | 56.42B | |
| -0.34% | +2.91% | +45.55% | +46.87% | 44.54B | |
| +0.17% | +6.33% | -14.50% | -19.55% | 22.9B | |
| 0.00% | +3.98% | -3.62% | +389.33% | 21.21B | |
| -0.51% | -5.56% | +10.43% | -29.97% | 16.4B | |
| -1.54% | -1.06% | +8.10% | -39.28% | 15.4B | |
| -0.62% | +1.68% | +26.01% | +175.45% | 13.35B | |
| +0.96% | +6.56% | +20.81% | - | 12.36B | |
| +0.32% | +1.60% | +96.37% | +207.56% | 11.15B | |
| Average | -0.50% | +1.66% | +27.41% | +105.17% | 23.75B | |
| Weighted average by Cap. | -0.97% | +2.54% | +32.02% | +97.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -50M -43.1M -39.66M -37.21M -69.89M -4.73B -70.59M -469M -183M -2.31B -188M -184M -8.01B | -66.25M -57.1M -52.55M -49.3M -92.61M -6.26B -93.53M -621M -243M -3.07B -249M -243M -10.61B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
